Concepedia

Author

Antoni Jou

Hospital Universitari Germans Trias i Pujol

Also Known As

A Jou, A. Jou, Ana González-Cordon, Antoni Jou, B Clotet, B. Clotet, C. Quereda, E. Martínez, Lorna Leal, S. Moreno

44

Publications

1.8K

Citations

22

H-Index

35

Concepts

All Affiliations

Hospital Universitari Germans Trias i PujolUniversitat Autònoma de BarcelonaRed de Investigación en SidaIrsiCaixaInstitut d'Investigació en Ciències de la Salut Germans Trias i Pujol
AJ

About

Antoni Jou is an author at Hospital Universitari Germans Trias i Pujol specializing in medicine, hiv, and immunology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

432

2

Immunology

5

5

367

3

Public Health

3

3

65

4

Epidemiology

2

2

22

5

Hepatology

1

1

11

Antoni Jou

×

20

Publications

1.4K

Citations

17

H-Index

YearCitations

Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy

Albert Tuldrà, Carmina R. Fumaz, Ma José Ferrer,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2000

248

Long‐Lasting Remission of Cytomegalovirus Retinitis without Maintenance Therapy in Human Immunodeficiency Virus‐Infected Patients

C. Tural, Joan Romeu, G. Sirera,

The Journal of Infectious Diseases

1998

197

Virological, Immunological, and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efavirenz in Patients with Human Immunodeficiency Virus Infection and Long-Lasting Viral Suppression

Eugènia Negredo, Luís A. B. Cruz, Roger Paredes,

Clinical Infectious Diseases

2002

170

Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With HIV and Hepatitis C Virus

Juan Berenguer, Elisa Boucourt Rodríguez, Pilar Miralles,

Clinical Infectious Diseases

2012

159

Efficacy of Low‐Dose Subcutaneous Interleukin‐2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with ⩽250/μL CD4 T Cells and Undetectable Plasma Virus Load

Lidia Ruíz, Manel Juan, Antoni Jou,

The Journal of Infectious Diseases

1999

107

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Daniel K. Nomah, Juliana Reyes‐Urueña, Yesika Díaz,

The Lancet HIV

2021

106

Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients

Juan Macı́as, Juan González, Cristina Tural,

AIDS

2014

87

Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection

Phillippe Hermans, Willy Rozenbaum, Antoni Jou,

AIDS

1996

44

Prospective Randomized Two-Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long-Term Adherence to Highly Active Antiretroviral Therapy

Albert Tuldr, Carmina R. Fumaz, Ma Jos Ferrer,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2000

43

Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4<sup>+</sup>T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy

Sara Morón‐López, Elisabet Gómez‐Mora, María Salgado,

The Journal of Infectious Diseases

2015

38

Page 1